VIVIS, a subsidiary of Neutra Corp (NTRR) Stock Extends Rally: Jumps 47% in a Week
VIVIS, a subsidiary of Neutra Corp (OTCMKTS:NTRR), has signed a letter of intent (LOI) with a clinical research company in Houston that would enable them to test hemp-based cannabinoids for the treatment of COVID-19. VIVIS plans to work with Mercury Clinical Research to start phase 1 clinical trials on the efficacy of CBD in treating SARS-COVID-2. They might also use the trials to find other uses of ant-inflammation,appetite suppressant, anti-insomnia,…